BMO Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) but lowers the price target from $63 to $40.
July 18, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) but lowers the price target from $63 to $40.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100